What United Biosource Corporation does

United BioSource Corporation (UBC) is a privately held, US-headquartered contract research organization (CRO) founded in 2003 that operates across more than seven countries, delivering integrated specialty therapy commercialization services to biopharmaceutical sponsors. The company organizes its offering around three service pillars — Evidence Development (real-world evidence, late-stage research, registries, post-approval studies), Safety & Risk Management (pharmacovigilance and Risk Evaluation and Mitigation Strategies/REMS), and Patient Access (hub services including benefit verification, prior authorization, affordability, and adherence programs) — unified through a shared technology layer.

UBC's technology stack includes proprietary platforms AccessEdge (AI-driven payer management and benefit verification across 3,000+ payer accounts), AccessWay (digital enrollment reducing missing data by 60%), RAPID (standards-based API for REMS pharmacy integration), CLÆRITY (integrated evidence and access platform), and SæfetyWorks (safety platform). AI capabilities are embedded across pharmacovigilance (case narrative generation, MedDRA coding, OCR-based document processing, case triage), evidence synthesis (AI-enabled PRISMA-compliant systematic literature reviews, RAG-based SOP lookup), and patient access (predictive analytics for prior authorization). The company augments these capabilities through wholly owned subsidiaries: Examoto (REMS technology), Marketshare Movers (drug benefit and affordability analytics), and Evidinno Outcomes Research (HEOR and HTA-grade evidence synthesis, acquired January 2026).

Revenue is generated primarily through B2B professional services engagements with biopharma sponsors, supplemented by managed services for patient hubs and recurring/subscription revenue from technology platform licensing (AccessEdge, RAPID). Pricing is quote-based and project-specific with no public disclosure. The company has 1,001–5,000 employees, is led by CEO Bekki Bracken Brown, and recently formed a strategic partnership with Datavant (November 2025) to integrate privacy-preserving real-world data linkage across its evidence and access platforms. No public ownership, investor backing, or revenue figures were disclosed in the input data.

Name

United Biosource Corporation

Legal name

United BioSource LLC

Website

https://ubc.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

United BioSource Corporation (UBC) is a privately held global CRO that provides integrated evidence development, safety/risk management (REMS, pharmacovigilance), and patient access services to biopharmaceutical sponsors of specialty therapies across oncology, rare disease, and cell/gene therapy.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Clinical research services
• Pharmacovigilance solutions
• Real-world evidence
• Patient access services
• Risk management programs

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: UBC provides evidence generation, late-stage research, and real-world evidence services to biopharma sponsors. Revenue is generated through project-based professional service engagements for clinical trials, observational studies, registries, and post-approval research.
2. Pharmacovigilance & Risk Management: Comprehensive drug safety and global risk management solutions including REMS programs, adverse event processing, and regulatory compliance services.
3. Patient Access Services: Hub services including benefit verification, prior authorization, affordability solutions, copay programs, and patient adherence support for specialty therapies.
4. Technology Platform Licensing: AccessEdge platform and other technology solutions provided to pharmaceutical clients for patient access management and pharmacovigilance operations.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

United Biosource Corporation (UBC) is a contract research organization (CRO) providing biopharmaceutical sponsors with three integrated service pillars: Evidence Development Solutions (real-world evidence generation, modernized study design, late-stage research), Safety & Risk Management (pharmacovigilance and Risk Evaluation and Mitigation Strategies), and Patient Access Solutions (benefit verification, prior authorization, affordability, and adherence). The company operates proprietary technology platforms including AccessEdge (AI-driven payer management), RAPID (REMS pharmacy API), and AccessWay (digital enrollment), augmented by wholly owned subsidiaries Evidinno Outcomes Research, Examoto, and Marketshare Movers.

Product overview

UBC is a biopharma-focused Evidence Generation Solutions provider operating a platform-plus-modules architecture. The core platform connects three integrated service pillars — Evidence Development Solutions, Safety & Risk Management, and Patient Access Solutions — unified through a shared Technology infrastructure (Evidence Development technology, Safety & Risk Management technology, Patient Access technology, and Data & Analytics). Key products include AccessEdge (AI-powered payer management and benefit verification platform), AccessWay (digital enrollment), and RAPID (REMS pharmacy API integration). The portfolio is augmented by three wholly owned subsidiaries: Evidinno Outcomes Research (real-world evidence, HEOR, and evidence synthesis), Marketshare Movers (prescription drug benefit and affordability analytics), and Examoto (REMS risk mitigation services). UBC also holds branded trademarks including CLÆRITY (integrated evidence and access platform), SæfetyWorks (safety platform), ExpressConnect, and UBC Pathways (patient support programs). The Datavant partnership enables privacy-preserving data linkage connecting UBC's patient access operations and evidence generation platform with a healthcare data ecosystem of 350+ data partners.

Differentiator

Problem solved

Functional benefit

Brands

• UBC Pathways: Trademarked brand of United BioSource LLC
• CLÆRITY
• SæfetyWorks
• ExpressConnect
• AccessEdge
• AccessWay
• RAPID

Products and services

• Evidence Development Solutions Expert-led evidence generation solutions spanning integrated evidence generation strategy, modernized study design and execution, and late-stage research for biopharmaceutical sponsors developing specialty therapies, rare disease treatments, cell and gene therapies, and oncology products.
• Safety & Risk Management (Pharmacovigilance and REMS) Comprehensive drug safety and global risk management solutions for biopharma sponsors, encompassing Risk Evaluation and Mitigation Strategies (REMS) design and pharmacy integration, pharmacovigilance case processing, narrative generation, causality assessment, and regulatory compliance across FDA, EMA, Health Canada, and other authorities.
• Patient Access Solutions Hub services for biopharma sponsors combining benefit verification, prior authorization, appeals management, copay assistance, patient assistance programs, and omnichannel adherence programs to connect specialty therapy patients to their treatments.
• AccessEdge Platform AI-driven payer management platform for patient access and benefit verification, featuring deep patient-specific payer account intelligence, 3,000+ payer best practices, drug-specific therapy controls, and automated coding intelligence for prior authorization submissions. Sold as a standalone platform to pharmaceutical clients.
• RAPID (REMS API Integration) Standards-based API integration solution for REMS pharmacy workflows that streamlines REMS activities directly within pharmacy systems, reducing manual burden and improving data quality for biopharma sponsors operating REMS programs.
• Evidinno Outcomes Research Vancouver-based wholly owned subsidiary providing healthcare research consulting specializing in real-world evidence, epidemiology, HTA- and regulatory-grade evidence synthesis, AI-enabled literature reviews, network meta-analyses, economic modeling, and HTA dossier development for biopharma clients worldwide.
• Examoto REMS Services Wholly owned subsidiary providing technology and innovative design capabilities for REMS risk mitigation services, enhancing UBC's comprehensive REMS offerings for pharmaceutical clients.
• Marketshare Movers Affordability Solutions Wholly owned subsidiary providing data-driven prescription drug benefit and affordability solutions, including modeling and analytics tools for patient access programs, copay optimization, accumulator/maximizer programs, and foundation enrollment support.

Quantifiable outcome

• Reduces missing enrollment information by 60%
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Evidinno Outcomes Research Inc.coreStrategic or Co-development Partner · 5 January 2026UBC acquired Evidinno Outcomes Research Inc., a Vancouver-based healthcare research consulting firm specializing in real-world evidence, epidemiology, and health economic outcomes research (HEOR). Evidinno operates as a wholly owned subsidiary within UBC. The acquisition integrates Evidinno's HTA- and regulatory-grade evidence synthesis solutions, AI-enabled literature reviews, and economic modeling capabilities into UBC's global platform. Evidinno's team and capabilities enhance UBC's scientific and methodological expertise for serving biopharma clients worldwide.
• DatavantcoreStrategic or Co-development Partner · 20 November 2025Datavant and UBC formed a strategic partnership to transform late-phase research and patient access programs for biopharmaceutical sponsors. The collaboration combines Datavant's privacy-first data connectivity and 350+ data partner ecosystem with UBC's expertise in specialty therapies. Two initial joint offerings were launched: Modern Observational Research Study Designs and Enhanced Patient Access Programs. The partnership aims to accelerate evidence generation, improve patient outcomes, and set a new standard for real-world research and access through privacy-preserving data linkage.
• Examoto, LLCcoreStrategic or Co-development Partner · 28 July 2022UBC acquired Examoto, LLC, a REMS company specializing in risk mitigation services in the pharmaceutical industry. Examoto provides technology and innovative design for REMS programs. The acquisition enhanced UBC's REMS services, creating a comprehensive risk mitigation solution for pharmaceutical clients.
• MarketShare Movers (MSM)coreStrategic or Co-development Partner · 9 March 2022UBC acquired MarketShare Movers (MSM), a company specializing in data-driven prescription drug benefit and affordability solutions. The acquisition integrated MSM's modeling and analytics tools to improve patient access and affordability programs, expanding UBC's services to include innovative affordability solutions.
• Fairmount PartnersminorOthersFairmount Partners acted as the exclusive financial advisor to Evidinno Outcomes Research Inc. in the acquisition transaction completed January 2026.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ICON plc: Global clinical CRO formed via PRA Health Sciences combination, with strong post-approval and real-world evidence capabilities. Competes with UBC for late-stage and specialty-therapy clinical engagements.
• Syneos Health: Clinical-to-commercial CRO offering clinical development, commercialization, and patient access services. Overlaps with UBC's Evidence Development and Patient Access pillars and is a natural bid for the same specialty-therapy sponsors.
• Parexel International: Mid-to-large global CRO with deep biotech and specialty-therapy focus. Overlaps with UBC on late-stage clinical research, biostatistics, and pharmacovigilance services for biopharma sponsors.
• IQVIA: The largest global CRO and life sciences technology vendor. Directly comparable to UBC across clinical research, real-world evidence, pharmacovigilance, and technology-enabled patient services, though at substantially greater scale and breadth.
• Medpace Holdings: Mid-sized clinical CRO with full-service Phase I–IV capabilities and a strong biotech/specialty-therapy client base. Competes with UBC for late-stage and post-approval clinical work.
• Worldwide Clinical Trials: Mid-sized global CRO focused on complex therapeutic areas including rare disease and CNS. Directly comparable to UBC for specialty-therapy and post-approval clinical research.
• Evidera (PPD / Thermo Fisher Scientific): Specialized RWE and HEOR consulting business within PPD/Thermo Fisher. Direct competitor to UBC and Evidinno on HTA-grade evidence synthesis, real-world evidence, and market access support.
• Trinity Life Sciences: Life sciences consulting and evidence provider with RWE, HEOR, and market access capabilities. Closely comparable to UBC's Evidinno subsidiary on regulatory-grade evidence synthesis and HTA submissions.

Broad incumbents

• Labcorp Drug Development (now Fortrea): Spun off from Labcorp, this large CRO offers clinical development and central lab services overlapping with UBC's evidence development and lab-adjacent offerings, but at substantially larger scale.
• Charles River Laboratories: Large preclinical and clinical services provider with safety assessment and pharmacovigilance capabilities. Comparable to UBC on the safety/risk management side and on biopharma sponsor relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/UBCPharma
• LinkedInlinkedin.com/company/united-biosource-corporation

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about United Biosource Corporation